Greek trademarks committee rules GSK and GMK are dissimilar
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Sponsored content

Greek trademarks committee rules GSK and GMK are dissimilar

Sponsored by

patrinos-logo.png
Trademark Registration Concept

Evangelia Sioumala of Patrinos & Kilimiris suggests some of the reasoning applied in a decision by the Greek Trademarks Administrative Committee is not in line with settled EU case law

In a recent opposition brought before the Greek Trademarks Administrative Committee (TAC), which is the competent body to decide on oppositions, the TAC considered whether a trademark, below right, seeking registration in classes 5 and 10 is confusingly similar to an earlier trademark, below left, registered in the same classes.

Patrinos.JPG

In its judgment in January 2024, the TAC made reference to settled EU case law; according to which, the overall assessment of the likelihood of confusion must be based on the overall impression given by the marks being compared, bearing in mind, inter alia, their distinctive and dominant elements (C-342/97, Section 18, and C-251/95, Section 22).

Nevertheless, even though the TAC found that the dominant wordsof the trademarks compared (“GSK” and “GMK”) are almost identical in that they consist of three letters, two of which are identical and reproduced in the same order, it concluded that they are not confusingly similar, as the addition of the word “medical” and a cross to the contested trademark suffice to exclude the likelihood of confusion.

Apparent points of divergence with settled EU case law

The ruling does not seem to be in line with settled EU case law; according to which, the difference in a single letter does not constitute a visual and aural difference in marks consisting of only three letters, two out of three of which are identical and in the same order (T-388/00, Sections 66–71).

Furthermore, by ruling that the addition of the word “medical” differentiates the trademarks, the decision contradicted settled EU case law; according to which, the word “medi” or “medical” is not capable of distinguishing goods in the pharmaceutical sector. In addition, the meaning of the word is immediately perceptible to the Greek consumer. The decision also ignored the fact that the presence of a cross is commonplace in the health sector and has become established for the identification of medical products.

With regard to the similarity of the products, although the TAC stated that both trademarks covered products in classes 5 and 10, it concluded that the opponent company operates in the field of medicines and vaccines, while the applicant markets medical devices, thus they are two undertakings with different activities and geographical coverage. The above reasoning is contrary to settled case law that geographical origin is not relevant for the finding of similarity of goods or services.

Finally, the TAC ruled that due to the nature of the products concerned (pharmaceuticals), the degree of attention of the relevant public is high, again contradicting settled case law (T-323/14, Section 77, and C-342/97, Section 18) that the relevant public’s level of attention being high is not, in any event, sufficient to rule out the likelihood of confusion.

The decision can be appealed, and it remains to be seen whether the above reasoning of the TAC will survive a more thorough examination by the higher competent body.

more from across site and ros bottom lb

More from across our site

Keith Bergelt, CEO of the Open Invention Network, explains why AI technologies were not part of an update to its cross-licensing project
Kirkland & Ellis partners explain how they secured the dismissal of a patent case in which the other side had lied under oath
Managing IP understands the association had been considering other options, including Madrid or Vienna, after concerns were raised over Dubai’s positions on various rights
Chris Marando tells Managing IP that he's excited to work on PTAB matters at Perkins Coie, which recently hired another lawyer from his former firm
To mark Pride month, Darren Smyth, cochair of IP Out, says the legal profession must not forget that some members still face exclusion and hostility
Lawyers say the opening of the Milan central division this month is likely to boost activity in Italy, which has been modest so far
Sharon Urias tells us why she still has to explain the difference between copyright and trademarks
In the latest episode, Managing IP is joined by Gwilym Roberts and Lee Davies from the Chartered Institute of Patent Attorneys to discuss the UPC, IP ministers, diversity and more
Lawyers at Tomkins and Bomhard IP explain how they finally secured victory over McDonald’s in long-running ‘Big Mac’ trademark dispute
Technical excellence is paramount for clients looking to hire new advisers, according to a survey of nearly 29,000 corporate counsel
Gift this article